Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04446598
Other study ID # CPPS/CP-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 13, 2017
Est. completion date December 31, 2018

Study information

Verified date June 2020
Source Espacio Gaspar Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective study aimed to compare the clinical outcomes between the use of the erbium: YAG (Er:YAG) laser, intraurethrally administered in long non-ablative SMOOTH™ train of pulses applied at the level of the male prostatic urethra, to the use of the pharmacological treatment of oral tadalafil for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The results show that both treatments are effective in alleviating symptoms of CP/CPPS. The non-ablative Er:YAG SMOOTHTM laser seems to be a promising treatment for this widely spread condition. More studies are needed to confirm its safety and efficacy.


Description:

Prostatitis is the most common diagnosis (>50%) in men visiting outpatient urological clinics .

The NIH classification classifies prostatitis into 4 types: category I - acute bacterial prostatitis, which is very rare, affecting only up to 5% of patients; category II- chronic bacterial prostatitis, also affecting up to 5% of patients; category III- chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS), which is the most common, as it affects 90%-95% of cases; and Category IV- asymptomatic inflammatory prostatitis, which has unknown prevalence and also unknown clinical significance.

Although category III or CP/CPPS is the most prevalent form of prostatitis, its causes are largely unknown and treatments often fail to alleviate symptoms in the long term. In contrast, patients suffering from type I and II prostatitis are successfully treated with antibiotics, as a uropathogen or an infectious agent is usually identified as the cause .

CP/CPPS is characterized by pain in the perineum and tenderness in the prostate and various urological symptoms (urgency, frequency, low urethral pressure) and sometimes also ejaculatory symptoms, such as painful ejaculation.

Currently used treatments for CP/CPPS are mainly pharmacological, including alpha blockers, 5-alpha reductase inhibitors, anti-inflammatories, antibiotics, phytotherapy, allopurinol, botulinum toxin and traditional Chinese medicine . Non-pharmacological therapies include acupuncture, prostatic massage, extracorporeal shockwave therapy, pulsed magnetic field therapy, transrectal and transurethral thermotherapy and others . Some of the abovementioned therapies alleviate symptoms by improving vascularisation and blood flow of the prostate and peri-prostatic area. This is also the mechanism of action of the erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode - it works by thermal pulsing of the treated surface, with microsecond-range long pulses combined into long (several hundred millisecond range) sequences. Each laser micropulse sharply increases tissue temperature and acts as a stimulative trigger. Long pulse trains cause slower diffusion of heat to deeper layers of the skin or mucosa, causing initially vasodilation and then collagen remodelling and stimulation of fibroblasts with collagen remodelling. It has shown to improve vascularisation and alleviate symptoms of genitourinary syndrome of menopause (GSM) in women, including irritation, dryness and pain. It has also been used intraurethrally in women to alleviate urinary symptoms of GSM. Intraurethral thermal therapy has been previously shown promising in the treatment of CP/CPPS in men. In this study the investigators aimed to assess the safety and effectiveness of transurethral non-ablative Er:YAG laser therapy applied at the level of the male prostatic urethra and to compare it with pharmacological treatment of 5 mg oral tadalafil for the treatment of CP/CPPS.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 31, 2018
Est. primary completion date November 30, 2018
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- clinical diagnosis of chronic prostatitis/chronic pelvic pain syndrome with characteristic symptoms of perineal pain and urinary symptoms of dysuria and urinary frequency;

- negative urine culture after prostatic massage; prostatic volume less than 50 cc in prostatic ultrasound;

- obstructive uroflowmetric pattern with a Q-max value between 10 and 15 ml/sec

Exclusion Criteria:

- age over 50 years

- current or recent (last 6 months) pharmacological or other therapies of CP/CPPS

Study Design


Related Conditions & MeSH terms


Intervention

Device:
non-ablative SMOOTH mode Erbium YAG laser
Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
Drug:
Tadalafil 5mg
oral tadalafil 5 mg was administered daily over a period of two months

Locations

Country Name City State
Argentina Uroclinica Mendoza

Sponsors (1)

Lead Sponsor Collaborator
Adrian Gaspar

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum urethral flow value (Q-max) measurement of maximum urethral flow using uroflowmetry Change from Baseline Q-max at 3 and 6 months following the intervention
Primary IPSS questionnaire Assessment of urinary symptoms using the International Prostate Symptom Score (IPSS) Change from Baseline IPSS score at 1, 3, 6 and 12 months following the intervention
Secondary pain assesment: VAS (visual analog scale) scale subjective assesment of pain using 0 (minimum) to 10 (maximum) VAS scale. 0 means no pain, 10 means worst possible pain; Change from Baseline pain VAS score at 1, 3, 6 and 12 months following the intervention
Secondary dysuria assesment: VAS (visual analog scale) scale subjective assesment of dysuria using 0 (minimum) to 10 (maximum) VAS scale. 0 means no dysuria, 10 means worst possible dysuria; Change from Baseline dysuria VAS score at 1,3, 6 and 12 months following the intervention
Secondary Patient satisfaction: 7-point Likert Scale subjective assessment of patients' satisfaction with the treatment using 0 to 6 Likert Scale; Question - How satisfied are you with the treatment? Likert scale: 0 - extremely satisfied; 1- very satisfied; 2 - mostly satisfied; 3 - neither satisfied nor unsatisfied; 4 - mostly unsatisfied; 5 - very unsatisfied; 6- extremely unsatisfied 6 months following the intervention
Secondary Patient satisfaction: 7-point Likert Scale subjective assessment of patients' satisfaction with the treatment using 0 to 6 Likert Scale; Question - How satisfied are you with the treatment? Likert scale: 0 - extremely satisfied; 1- very satisfied; 2 - mostly satisfied; 3 - neither satisfied nor unsatisfied; 4 - mostly unsatisfied; 5 - very unsatisfied; 6- extremely unsatisfied 12 months following the intervention
See also
  Status Clinical Trial Phase
Completed NCT04552431 - Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin Phase 2
Not yet recruiting NCT05366517 - Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome N/A
Terminated NCT02385266 - Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Phase 4
Completed NCT00672087 - Diagnostic Challenges in IC (and Male CPPS)
Completed NCT03213938 - Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome N/A
Recruiting NCT00775515 - Laparoscopic Prostatectomy for Chronic Prostatitis Phase 2
Completed NCT01676857 - Chemokine Mechanisms in Chronic Pelvic Pain
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT00826514 - An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Phase 2
Completed NCT06064448 - Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction Phase 4
Completed NCT00701311 - An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 2
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Active, not recruiting NCT05075551 - Analyzing the Brain Alterations of Acupuncture on Patients With CP/CPPS Evaluated by fMRI N/A
Recruiting NCT06385977 - Risk Factors for Chronic Prostatitis Patients in Northwest China
Completed NCT06016595 - Chronic Prostatitis/Chronic Pelvic Pain Syndrome Patients
Active, not recruiting NCT01828996 - Shocking Therapy for Chronic Pelvic Pain Syndrome N/A
Recruiting NCT03629769 - Effects of Proxelan Somministration in Patients With Chronic Prostatitis Phase 3
Recruiting NCT06345014 - The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 4
Recruiting NCT06115083 - Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective Outcomes N/A
Completed NCT03167216 - Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction Early Phase 1